The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×4•Originally published 16 April 2026•Updated 18 April 2026•

1 min read

Novo Nordisk Expands Obesity Portfolio with Wegovy HD Launch and New Oral Pill

Key Facts

1GLP-1 drugs showed direct beneficial effects on the liver in mice with fatty liver disease.

about 2 months ago

Version History

Version 4about 2 months ago

What changed: Updated with new prescription data showing a slow initial uptake for Eli Lilly's rival pill compared to Novo Nordisk's expansion.

Version 3about 2 months ago

What changed: The story was updated to reflect the commercial launch of the higher-dose Wegovy HD injection in the U.S. and the market-expanding impact of the new oral pill.

Version 2about 2 months ago

What changed: Updated the story to include the decline in Eli Lilly's stock following the FDA's request for additional safety data for its drug Foundayo.

Version 1about 2 months ago

What changed: The story was updated to include new data from Hoth Therapeutics regarding a genetic treatment for fatty liver disease as an alternative or competitor to GLP-1 drugs.

Novo Nordisk has officially launched its higher-dose Wegovy HD injection in the United States, strengthening its position in the competitive metabolic market. Simultaneously, the introduction of the new Wegovy pill aims to expand the patient base as competitors face a slow start. According to recent data, Eli Lilly recorded only 1,390 prescriptions for its newly launched obesity pill in the U.S. for the week ended April 10. IQVIA data indicates modest initial uptake for Eli Lilly's competing product compared to Novo Nordisk's aggressive expansion. These commercial milestones coincide with clinical findings showing that GLP-1 drugs provide direct liver benefits independent of weight loss. Investors are now focused on how this disparity in prescription volume will solidify Novo Nordisk’s market lead.